Cargando…
Correction: Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosis
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
BMJ Publishing Group
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8313866/ https://www.ncbi.nlm.nih.gov/pubmed/34396130 http://dx.doi.org/10.1136/bmjno-2020-000096corr1 |
| _version_ | 1783729432455806976 |
|---|---|
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8313866 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | BMJ Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-83138662021-08-13 Correction: Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosis BMJ Neurol Open Correction BMJ Publishing Group 2021-07-23 /pmc/articles/PMC8313866/ /pubmed/34396130 http://dx.doi.org/10.1136/bmjno-2020-000096corr1 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
| spellingShingle | Correction Correction: Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosis |
| title | Correction: Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosis |
| title_full | Correction: Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosis |
| title_fullStr | Correction: Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosis |
| title_full_unstemmed | Correction: Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosis |
| title_short | Correction: Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosis |
| title_sort | correction: bortezomib for anti-nmdar encephalitis following daclizumab treatment in a patient with multiple sclerosis |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8313866/ https://www.ncbi.nlm.nih.gov/pubmed/34396130 http://dx.doi.org/10.1136/bmjno-2020-000096corr1 |